Reference is made to the stock exchange announcement published by
As of this date, the Company has been informed that certain primary insiders and close associates have been allocated new shares in the Rights Issue, as set out in the attached mandatory notifications of trade.
This information is subject to the disclosure requirements pursuant to article 19 of the EU Market Abuse Regulation and section 5-12 of the Norwegian Securities Trading Act.
For further information about the Company, please contact:
Mobile: +47 916 24 683
E-mail: rune.nystad@observemedical.com
Per Arne Nygård, CFO Observe Medical
Mobile: +47 411 04 345
E-mail: perarne.nygard@observemedical.com
About
The Company seeks to drive growth by leveraging its expertise in sales and commercialization of its broad portfolio of medical technology products, mainly in urine measurement, ultrasound, anesthesiology/ICUs, surgery and wound care, in combination with targeted M&A.
The Company is headquartered in
Further information is available at www.observemedical.com.
https://news.cision.com/observe-medical-asa/r/observe-medical-asa--allocation-of-offer-shares-to-primary-insiders-and-close-associates,c3893000
https://mb.cision.com/Main/19175/3893000/2491087.pdf
(c) 2023 Cision. All rights reserved., source